Cargando…

Aspirin Attenuates Hyperoxia-Induced Acute Respiratory Distress Syndrome (ARDS) by Suppressing Pulmonary Inflammation via the NF-κB Signaling Pathway

Acute respiratory distress syndrome (ARDS) is a common destructive syndrome with high morbidity and mortality rates. Currently, few effective therapeutic interventions for ARDS are available. Clinical trials have shown that the effectiveness of aspirin is inconsistent. The contribution of platelets...

Descripción completa

Detalles Bibliográficos
Autores principales: Tung, Yu-Tang, Wei, Chi-Hsuan, Yen, Chih-Ching, Lee, Po-Ying, Ware, Lorraine B., Huang, Hao-En, Chen, Wei, Chen, Chuan-Mu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802116/
https://www.ncbi.nlm.nih.gov/pubmed/35111059
http://dx.doi.org/10.3389/fphar.2021.793107
_version_ 1784642608592584704
author Tung, Yu-Tang
Wei, Chi-Hsuan
Yen, Chih-Ching
Lee, Po-Ying
Ware, Lorraine B.
Huang, Hao-En
Chen, Wei
Chen, Chuan-Mu
author_facet Tung, Yu-Tang
Wei, Chi-Hsuan
Yen, Chih-Ching
Lee, Po-Ying
Ware, Lorraine B.
Huang, Hao-En
Chen, Wei
Chen, Chuan-Mu
author_sort Tung, Yu-Tang
collection PubMed
description Acute respiratory distress syndrome (ARDS) is a common destructive syndrome with high morbidity and mortality rates. Currently, few effective therapeutic interventions for ARDS are available. Clinical trials have shown that the effectiveness of aspirin is inconsistent. The contribution of platelets to the inflammatory response leading to the development of ARDS is increasingly recognized. The antiplatelet agent aspirin reportedly exerts a protective effect on acid- and hyperoxia-induced lung injury in murine models. Our previous study showed that pretreatment with aspirin exerts protective effects on hyperoxia-induced lung injury in mice. However, the mechanisms and therapeutic efficacy of aspirin in the posttreatment of hyperoxia-induced acute lung injury (ALI) remain unclear. In this study, we used a homozygous NF-κB-luciferase(+/+) transgenic mouse model and treated mice with low-dose (25 μg/g) or high-dose (50 μg/g) aspirin at 0, 24, and 48 h after exposure to hyperoxia (inspired oxygen fraction (FiO(2)) > 95%). Hyperoxia-induced lung injury significantly increased the activation of NF-κB in the lung and increased the levels of macrophages infiltrating the lung and reactive oxygen species (ROS), increased the HO-1, NF-κB, TNF-α, IL-1β, and IL-4 protein levels, and reduced the CC10, SPC, eNOS, Nrp-1, and IκBα protein levels in the lung tissue. Pulmonary edema and alveolar infiltration of neutrophils were also observed in the lung tissue of mice exposed to hyperoxia. However, in vivo imaging revealed that posttreatment with aspirin reduced luciferase expression, suggesting that aspirin might reduce NF-κB activation. Posttreatment with aspirin also reduced hyperoxia-induced increases in the numbers of lung macrophages, intracellular ROS levels, and the expression of TNF-α, IL-1β, and IL-4; it also increased CC10, SPC and Nrp-1 levels compared with hyperoxia exposure alone. Lung histopathology also indicated that the aspirin posttreatment significantly reduced neutrophil infiltration and lung edema compared with hyperoxia exposure alone. Aspirin effectively induces an anti-inflammatory response in a model of hyperoxia-induced lung injury. Thus, aspirin may have potential as a novel treatment for hyperoxia-induced ALI.
format Online
Article
Text
id pubmed-8802116
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88021162022-02-01 Aspirin Attenuates Hyperoxia-Induced Acute Respiratory Distress Syndrome (ARDS) by Suppressing Pulmonary Inflammation via the NF-κB Signaling Pathway Tung, Yu-Tang Wei, Chi-Hsuan Yen, Chih-Ching Lee, Po-Ying Ware, Lorraine B. Huang, Hao-En Chen, Wei Chen, Chuan-Mu Front Pharmacol Pharmacology Acute respiratory distress syndrome (ARDS) is a common destructive syndrome with high morbidity and mortality rates. Currently, few effective therapeutic interventions for ARDS are available. Clinical trials have shown that the effectiveness of aspirin is inconsistent. The contribution of platelets to the inflammatory response leading to the development of ARDS is increasingly recognized. The antiplatelet agent aspirin reportedly exerts a protective effect on acid- and hyperoxia-induced lung injury in murine models. Our previous study showed that pretreatment with aspirin exerts protective effects on hyperoxia-induced lung injury in mice. However, the mechanisms and therapeutic efficacy of aspirin in the posttreatment of hyperoxia-induced acute lung injury (ALI) remain unclear. In this study, we used a homozygous NF-κB-luciferase(+/+) transgenic mouse model and treated mice with low-dose (25 μg/g) or high-dose (50 μg/g) aspirin at 0, 24, and 48 h after exposure to hyperoxia (inspired oxygen fraction (FiO(2)) > 95%). Hyperoxia-induced lung injury significantly increased the activation of NF-κB in the lung and increased the levels of macrophages infiltrating the lung and reactive oxygen species (ROS), increased the HO-1, NF-κB, TNF-α, IL-1β, and IL-4 protein levels, and reduced the CC10, SPC, eNOS, Nrp-1, and IκBα protein levels in the lung tissue. Pulmonary edema and alveolar infiltration of neutrophils were also observed in the lung tissue of mice exposed to hyperoxia. However, in vivo imaging revealed that posttreatment with aspirin reduced luciferase expression, suggesting that aspirin might reduce NF-κB activation. Posttreatment with aspirin also reduced hyperoxia-induced increases in the numbers of lung macrophages, intracellular ROS levels, and the expression of TNF-α, IL-1β, and IL-4; it also increased CC10, SPC and Nrp-1 levels compared with hyperoxia exposure alone. Lung histopathology also indicated that the aspirin posttreatment significantly reduced neutrophil infiltration and lung edema compared with hyperoxia exposure alone. Aspirin effectively induces an anti-inflammatory response in a model of hyperoxia-induced lung injury. Thus, aspirin may have potential as a novel treatment for hyperoxia-induced ALI. Frontiers Media S.A. 2022-01-17 /pmc/articles/PMC8802116/ /pubmed/35111059 http://dx.doi.org/10.3389/fphar.2021.793107 Text en Copyright © 2022 Tung, Wei, Yen, Lee, Ware, Huang, Chen and Chen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Tung, Yu-Tang
Wei, Chi-Hsuan
Yen, Chih-Ching
Lee, Po-Ying
Ware, Lorraine B.
Huang, Hao-En
Chen, Wei
Chen, Chuan-Mu
Aspirin Attenuates Hyperoxia-Induced Acute Respiratory Distress Syndrome (ARDS) by Suppressing Pulmonary Inflammation via the NF-κB Signaling Pathway
title Aspirin Attenuates Hyperoxia-Induced Acute Respiratory Distress Syndrome (ARDS) by Suppressing Pulmonary Inflammation via the NF-κB Signaling Pathway
title_full Aspirin Attenuates Hyperoxia-Induced Acute Respiratory Distress Syndrome (ARDS) by Suppressing Pulmonary Inflammation via the NF-κB Signaling Pathway
title_fullStr Aspirin Attenuates Hyperoxia-Induced Acute Respiratory Distress Syndrome (ARDS) by Suppressing Pulmonary Inflammation via the NF-κB Signaling Pathway
title_full_unstemmed Aspirin Attenuates Hyperoxia-Induced Acute Respiratory Distress Syndrome (ARDS) by Suppressing Pulmonary Inflammation via the NF-κB Signaling Pathway
title_short Aspirin Attenuates Hyperoxia-Induced Acute Respiratory Distress Syndrome (ARDS) by Suppressing Pulmonary Inflammation via the NF-κB Signaling Pathway
title_sort aspirin attenuates hyperoxia-induced acute respiratory distress syndrome (ards) by suppressing pulmonary inflammation via the nf-κb signaling pathway
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802116/
https://www.ncbi.nlm.nih.gov/pubmed/35111059
http://dx.doi.org/10.3389/fphar.2021.793107
work_keys_str_mv AT tungyutang aspirinattenuateshyperoxiainducedacuterespiratorydistresssyndromeardsbysuppressingpulmonaryinflammationviathenfkbsignalingpathway
AT weichihsuan aspirinattenuateshyperoxiainducedacuterespiratorydistresssyndromeardsbysuppressingpulmonaryinflammationviathenfkbsignalingpathway
AT yenchihching aspirinattenuateshyperoxiainducedacuterespiratorydistresssyndromeardsbysuppressingpulmonaryinflammationviathenfkbsignalingpathway
AT leepoying aspirinattenuateshyperoxiainducedacuterespiratorydistresssyndromeardsbysuppressingpulmonaryinflammationviathenfkbsignalingpathway
AT warelorraineb aspirinattenuateshyperoxiainducedacuterespiratorydistresssyndromeardsbysuppressingpulmonaryinflammationviathenfkbsignalingpathway
AT huanghaoen aspirinattenuateshyperoxiainducedacuterespiratorydistresssyndromeardsbysuppressingpulmonaryinflammationviathenfkbsignalingpathway
AT chenwei aspirinattenuateshyperoxiainducedacuterespiratorydistresssyndromeardsbysuppressingpulmonaryinflammationviathenfkbsignalingpathway
AT chenchuanmu aspirinattenuateshyperoxiainducedacuterespiratorydistresssyndromeardsbysuppressingpulmonaryinflammationviathenfkbsignalingpathway